TPST Tempest Tx Total Debt to Capital

TPST (Tempest Therapeutics, Inc.) - company brandmark

The current market quotes for Tempest Therapeutics (TPST) visualized below demonstrate financial resilience amid growing demand for drugs targeting solid tumors and liver cancer. The individual debt-to-equity ratio stands at 0.00. Tempest Therapeutics (TPST) develops small molecules for immune management in oncology, leveraging a powerful scientific resource. Simultaneously, the business is implementing environmental filters and conserving water in its laboratories.

Debt to Equity Ratio: tempesttx.com (TPST) for 07/04/2022 - 10/28/2026
Product sample of Tempest Therapeutics

For Tempest Therapeutics (TPST), whose model relies on costly oncology R&D without current revenue, the debt-to-equity ratio chart reflects the funding stability of its pipeline. This ratio compares total liabilities to net asset value, determining the degree of dependence on borrowed funds and the risk of capital degradation amid price volatility or changes in Fed rates.

Main competitors

Total Debt to Capital ONC|Total Debt to Equity Ratio Halozyme Therapeutics, Inc.|Total Debt to Capital RVMD|Total Debt to Capital AAPG (Ascentage Pharma Corp)|CGON - Debt to Equity|Debt to Equity Ratio urogen.com URGN|BCAX: Total Debt to Capital|PSNL - Total Debt to Equity Ratio|Total Debt to Capital ERAS|DCTH (Delcath Corp) - Debt to Capital|YMAB - Debt to Equity|All Debt to Shareholders' Equity Ratio aurabiosciences.com (AURA)|Candel Therapeutics (CADL) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio Accuray Inc (ARAY)|SELLAS Life Sciences Group - Total Debt to Capital|ACTU - Total Debt to Equity Ratio|Citius Oncology, Inc. - Total Debt to Equity Ratio|HURA: Total Debt to Capital|Debt to Equity Protara Therapeutics, Inc. TARA|Fate Therapeutics Inc (FATE) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital WHWK (Aadi Bioscience, Inc.)|Debt to Capital TScan (TCRX)|Total Debt to Equity Ratio Champions Oncology|Aggregate Debt to Capital xbiotech.com (XBIT)|CVM: Total Debt to Capital|OS Therapies Inc. - Debt to Capital|RADX: Debt to Equity|ARTV: Total Debt to Equity Ratio|Debt to Equity adlainortye.com (ANL)|verupharma.com (VERU) - Aggregate Debt to Equity|Total Debt to Capital XLO (Xilio Therapeutics Inc)|Debt to Capital RENB|MURA (Mural Oncology plc) - Debt to Equity|Total Debt to Capital Coefficient kairospharma.com KAPA|Total Debt to Equity Ratio OnKure Therapeutics (OKUR)|GDTC - Aggregate Debt to Capital|Total Debt to Equity Ratio Curis Corp (CRIS)|Apollomics, Inc. (APLM) - All Debt to Shareholders' Equity Ratio|THAR - Total Debt to Equity Ratio|Advanced Biomed (ADVB) - Aggregate Debt to Capital|GNPX - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Calidi Bio|Sunshine Biopharma, Inc. - Total Debt to Capital|Debt to Capital XBIO (xeneticbio.com)|Debt to Equity Salarius|All Debt to Shareholders' Equity Ratio Kitov Pharma PPBT|AON - Total Debt to Capital|BGNE: Total Debt to Capital|Debt to Equity Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com (ELEV) - Aggregate Debt to Equity|Total Debt to Capital ICAD (iCAD Inc.)|Debt to Capital Ikena (IKNA)|Total Debt to Equity Ratio NTBL|Total Debt to Capital viracta.com VIRX|Total Debt to Equity Ratio MorphoSys (MOR)|Aggregate Debt to Capital NAYA Biosciences Inc NAYA|Total Debt to Capital AAPGV (Ascentage Pharma Group Ltd)